June 11 - Novo Nordisk (NYSE:NVO) has teamed up with Nvidia (NASDAQ:NVDA) to integrate artificial intelligence into its drug development pipeline, aiming to speed up early-stage research, according to a Wednesday press release.

The collaboration will build AI models tailored for Novo Nordisk's researchers, helping simulate and optimize early clinical trial stages. The tools are designed to support work across advanced simulation platforms and physical AI systems.

• Warning! GuruFocus has detected 4 Warning Signs with NVDA.

This effort will also back Novo Nordisk's existing agreement with the Danish Centre for AI Innovation. That institution manages Gefion, Denmark's flagship AI supercomputer, which will play a key role in powering the new drug discovery tools.

Nvidia said the initiative will apply generative and agent-based AI to pharmaceutical R&D. The announcement came during the chipmaker's GTC event in Paris, where it also highlighted broader partnerships across Europe.

This article first appeared on GuruFocus.